Innovative Engineered Antibodies Enable T-Cells to Target and Destroy Cytomegalovirus-Infected Cells
Researchers have engineered bispecific antibodies that direct T-cells to effectively target and eliminate cytomegalovirus-infected cells, offering new hope for immunocompromised patients battling CMV infections.
Researchers from the University of California, Los Angeles (UCLA) have developed a groundbreaking method to enhance the immune response against cytomegalovirus (CMV), a significant pathogen especially dangerous to immunocompromised individuals. CMV infection, which persists for life once acquired, can cause severe health complications such as organ rejection in transplant patients, AIDS progression, and congenital deafness when transmitted during pregnancy.
Traditional treatment involves antiviral drugs that, despite their effectiveness, often come with serious side effects including bone marrow suppression and kidney damage, and the virus can develop resistance over time. To address this challenge, UCLA scientists engineered specialized antibodies known as T-cell redirecting bispecific antibodies (TRBAs). These antibodies act as a molecular bridge, connecting CD3-epsilon on cytotoxic T-cells (CTLs) to viral proteins expressed on infected cells.
By linking these immune cells directly to infected cells, the TRBAs promote clustering and activation of CTLs at the site of infection, resulting in targeted killing of the virus-harboring cells. This novel approach could offer a faster, more effective treatment option compared to current therapies that rely on adoptive T-cell transfer or chimeric antigen receptor (CAR) T-cell therapies, which are often time-consuming and complex to produce.
The research, led by Dr. Otto Yang, suggests that if developed commercially, these engineered antibodies could be tested in clinical trials to provide a new therapeutic avenue for preventing and treating CMV infections, particularly in vulnerable populations. The study has been published in the journal Science Advances.
This innovative strategy holds promise for expanding immune-based treatments that could circumvent the drawbacks of existing antiviral drugs, reducing side effects and defeating resistance, thereby significantly improving patient outcomes in CMV-related illnesses.
Source: [https://medicalxpress.com/news/2025-09-antibodies-cells-cytomegalovirus-infected.html]
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Understanding Retinol: Benefits, Risks, and Best Practices
Learn about retinol's benefits for aging and acne, its proper usage, potential side effects, and tips for safe application to achieve healthy, youthful skin.
CDC Withdraws Vaccine Presentation After Citation Error Discovered
The CDC has withdrawn a vaccine safety presentation after discovering that the cited study, claiming long-term brain effects from a preservative, did not exist, raising concerns over misinformation in public health communications.
Thin Endometrial Thickness May Not Limit IVF Success Rates
Emerging research indicates that a thin endometrial lining may not significantly hinder IVF success, opening new possibilities for patients with thinner uterine linings.
Semaglutide Shows Promise in Reducing Heart Disease Risk Within Six Months
Emerging research suggests that semaglutide, a diabetes and weight loss medication, may reduce the risk of major heart events within just six months of treatment, offering promising cardiovascular protection for at-risk individuals.